Inhibition of the methionine aminopeptidase 2 enzyme for the treatment of obesity

References

• World Health Organization [webpage on the Internet] Media centre fact sheets. Obesity and overweight Geneva World Health Organization 2013 Available from: http://www.who.int/mediacentre/factsheets/fs311/en/index.html Accessed October 22, 2013
   Google Scholar
• Kumanyika SK Obarzanek E Stettler N American Heart Association Council on Epidemiology and Prevention, Interdisciplinary Committee for Prevention Population-based prevention of obesity: the need for comprehensive promotion of healthful eating, physical activity, and energy balance: a scientific statement from American Heart Association Council on Epidemiology and Prevention, Interdisciplinary Committee for Prevention (formerly the expert panel on population and prevention science) Circulation 2008 118 4 428 464 18591433
   PubMed Web of Science ®Google Scholar
• Ogden CL Yanovski SZ Carroll MD Flegal KM The epidemiology of obesity Gastroenterology 2007 132 6 2087 2102 17498505
   PubMed Web of Science ®Google Scholar
• Nguyen DM El-Serag HB The epidemiology of obesity Gastroenterol Clin North Am 2010 39 1 1 7 20202574
   PubMed Web of Science ®Google Scholar
• Dietz WH Gortmaker SL Do we fatten our children at the television set? Obesity and television viewing in children and adolescents Pediatrics 1985 75 5 807 812 3873060
   PubMed Web of Science ®Google Scholar
• Holsten JE Obesity and the community food environment: a systematic review Public Health Nutr 2009 12 3 397 405 18477414
   PubMed Web of Science ®Google Scholar
• Prentice AM Jebb SA Obesity in Britain: gluttony or sloth? BMJ 1995 311 7002 437 439 7640595
   PubMed Web of Science ®Google Scholar
• Andreasen CH Andersen G Gene-environment interactions and obesity – further aspects of genomewide association studies Nutrition 2009 25 10 998 1003 19596186
   PubMed Web of Science ®Google Scholar
• Andreasen CH Stender-Petersen KL Mogensen MS Low physical activity accentuates the effect of the FTO rs9939609 polymorphism on body fat accumulation Diabetes 2008 57 1 95 101 17942823
   PubMed Web of Science ®Google Scholar
• Christakis NA Fowler JH The spread of obesity in a large social network over 32 years N Engl J Med 2007 357 4 370 379 17652652
   PubMed Web of Science ®Google Scholar
• Heal DJ Gosden J Smith SL Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders Br J Clin Pharmacol 2009 68 6 861 874 20002080
   PubMed Web of Science ®Google Scholar
• Adams KF Schatzkin A Harris TB Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old N Engl J Med 2006 355 8 763 778 16926275
   PubMed Web of Science ®Google Scholar
• Oster G Thompson D Edelsberg J Bird AP Colditz GA Lifetime health and economic benefits of weight loss among obese persons Am J Public Health 1999 89 10 1536 1542 10511836
   PubMed Web of Science ®Google Scholar
• Wu T Gao X Chen M van Dam RM Long-term effectiveness of diet-plus-exercise interventions vs diet-only interventions for weight loss: a meta-analysis Obes Rev 2009 10 3 313 323 19175510
   PubMed Web of Science ®Google Scholar
• Adan RA Mechanisms underlying current and future anti-obesity drugs Trends Neurosci 2013 36 2 133 140 23312373
   PubMed Web of Science ®Google Scholar
• Adan RA Mechanisms underlying current and future anti-obesity drugs Trends Neurosci 2013 36 2 133 140 23312373
   PubMed Web of Science ®Google Scholar
• Folkman J Angiogenesis in cancer, vascular, rheumatoid and other disease Nat Med 1995 1 1 27 31 7584949
   PubMed Web of Science ®Google Scholar
• Cao Y Angiogenesis modulates adipogenesis and obesity J Clin Invest 2007 117 9 2362 2368 17786229
   PubMed Web of Science ®Google Scholar
• Bukowiecki L Lupien J Follea N Paradis A Richard D LeBlanc J Mechanism of enhanced lipolysis in adipose tissue of exercise-trained rats Am J Physiol 1980 239 6 E422 E429 6255803
   PubMed Web of Science ®Google Scholar
• Gupta RK Mepani RJ Kleiner S Zfp423 expression identifies committed preadipocytes and localizes to adipose endothelial and perivascular cells Cell Metab 2012 15 2 230 239 22326224
   PubMed Web of Science ®Google Scholar
• Cao Y Endogenous angiogenesis inhibitors and their therapeutic implications Int J Biochem Cell Biol 2001 33 4 357 369 11312106
   PubMed Web of Science ®Google Scholar
• Sun K Wernstedt Asterholm I Kusminski CM Dichotomous effects of VEGF-A on adipose tissue dysfunction Proc Natl Acad Sci U S A 2012 109 15 5874 5879 22451920
   PubMed Web of Science ®Google Scholar
• Dobson DE Kambe A Block E 1-Butyryl-glycerol: a novel angiogenesis factor secreted by differentiating adipocytes Cell 1990 61 2 223 230 1691958
   PubMed Web of Science ®Google Scholar
• Mahadev K Wu X Donnelly S Ouedraogo R Eckhart AD Goldstein BJ Adiponectin inhibits vascular endothelial growth factor-induced migration of human coronary artery endothelial cells Cardiovasc Res 2008 78 2 376 384 18267956
   PubMed Web of Science ®Google Scholar
• Lijnen HR Angiogenesis and obesity Cardiovasc Res 2008 78 2 286 293 18006485
   PubMed Web of Science ®Google Scholar
• Kawaguchi N Toriyama K Nicodemou-Lena E Inou K Torii S Kitagawa Y De novo adipogenesis in mice at the site of injection of basement membrane and basic fibroblast growth factor Proc Natl Acad Sci U S A 1998 95 3 1062 1066 9448285
   PubMed Web of Science ®Google Scholar
• Davis S Aldrich TH Jones PF Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning Cell 1996 87 7 1161 1169 8980223
   PubMed Web of Science ®Google Scholar
• Christiaens V Lijnen HR Angiogenesis and development of adipose tissue Mol Cell Endocrinol 2010 318 1–2 2 9 19686803
   PubMed Web of Science ®Google Scholar
• Davis S Papadopoulos N Aldrich TH Angiopoietins have distinct modular domains essential for receptor binding, dimerization and superclustering Nat Struct Biol 2003 10 1 38 44 12469114
   PubMedGoogle Scholar
• Hadi HA Suwaidi JA Endothelial dysfunction in diabetes mellitus Vasc Health Risk Manag 2007 3 6 853 876 18200806
   PubMedGoogle Scholar
• Zafrir B Brown adipose tissue: research milestones of a potential player in human energy balance and obesity Horm Metab Res 2013 45 11 774 785 23803970
   PubMed Web of Science ®Google Scholar
• Yoneshiro T Aita S Matsushita M Recruited brown adipose tissue as an antiobesity agent in humans J Clin Invest 2013 123 8 3404 3408 23867622
   PubMed Web of Science ®Google Scholar
• Virtanen KA Lidell ME Orava J Functional brown adipose tissue in healthy adults N Engl J Med 2009 360 15 1518 1525 19357407
   PubMed Web of Science ®Google Scholar
• Saito M Okamatsu-Ogura Y Matsushita M High incidence of metabolically active brown adipose tissue in healthy adult humans: effects of cold exposure and adiposity Diabetes 2009 58 7 1526 1531 19401428
   PubMed Web of Science ®Google Scholar
• Kuo LE Kitlinska JB Tilan JU Neuropeptide Y acts directly in the periphery on fat tissue and mediates stress-induced obesity and metabolic syndrome Nat Med 2007 13 7 803 811 17603492
   PubMed Web of Science ®Google Scholar
• Tam J Duda DG Perentes JY Quadri RS Fukumura D Jain RK Blockade of VEGFR2 and not VEGFR1 can limit diet-induced fat tissue expansion: role of local versus bone marrow-derived endothelial cells PLoS One 2009 4 3 e4974 19333381
   PubMed Web of Science ®Google Scholar
• Cao R Brakenhielm E Wahlestedt C Thyberg J Cao Y Leptin induces vascular permeability and synergistically stimulates angiogenesis with FGF-2 and VEGF Proc Natl Acad Sci U S A 2001 98 11 6390 6395 11344271
   PubMed Web of Science ®Google Scholar
• Escudier B Eisen T Stadler WM TARGET Study Group Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 2007 356 2 125 134 17215530
   PubMed Web of Science ®Google Scholar
• Kerbel RS Tumor angiogenesis N Engl J Med 2008 358 19 2039 2049 18463380
   PubMed Web of Science ®Google Scholar
• Steinbrook R The price of sight – ranibizumab, bevacizumab, and the treatment of macular degeneration N Engl J Med 2006 355 14 1409 1412 17021315
   PubMed Web of Science ®Google Scholar
• Rupnick MA Panigrahy D Zhang CY Adipose tissue mass can be regulated through the vasculature Proc Natl Acad Sci U S A 2002 99 16 10730 10735 12149466
   PubMed Web of Science ®Google Scholar
• Duh E Aiello LP Vascular endothelial growth factor and diabetes: the agonist versus antagonist paradox Diabetes 1999 48 10 1899 1906 10512352
   PubMed Web of Science ®Google Scholar
• Gariano RF Gardner TW Retinal angiogenesis in development and disease Nature 2005 438 7070 960 966 16355161
   PubMed Web of Science ®Google Scholar
• Jackson R Hunter T Role of methionine in the initiation of haemoglobin synthesis Nature 1970 227 5259 672 676 5432061
   PubMed Web of Science ®Google Scholar
• Solbiati J Chapman-Smith A Miller JL Miller CG Cronan JE Processing of the N termini of nascent polypeptide chains requires deformylation prior to methionine removal J Mol Biol 1999 290 3 607 614 10395817
   PubMed Web of Science ®Google Scholar
• Selvakumar P Pasha MK Ashakumary L Dimmock JR Sharma RK Myristoyl-CoA:protein N-myristoyltransferase: a novel molecular approach for cancer therapy (Review) Int J Mol Med 2002 10 4 493 500 12239600
   PubMed Web of Science ®Google Scholar
• Bradshaw RA Brickey WW Walker KW N-terminal processing: the methionine aminopeptidase and N alpha-acetyl transferase families Trends Biochem Sci 1998 23 7 263 267 9697417
   PubMed Web of Science ®Google Scholar
• Arfin SM Kendall RL Hall L Eukaryotic methionyl aminopeptidases: two classes of cobalt-dependent enzymes Proc Natl Acad Sci U S A 1995 92 17 7714 7718 7644482
   PubMed Web of Science ®Google Scholar
• Selvakumar P Lakshmikuttyamma A Das U Pati HN Dimmock JR Sharma RK NC2213: a novel methionine aminopeptidase 2 inhibitor in human colon cancer HT29 cells Mol Cancer 2009 8 65 19703310
   PubMed Web of Science ®Google Scholar
• Catalano A Romano M Robuffo I Strizzi L Procopio A Methionine aminopeptidase-2 regulates human mesothelioma cell survival: role of Bcl-2 expression and telomerase activity Am J Pathol 2001 159 2 721 731 11485930
   PubMed Web of Science ®Google Scholar
• Ingber D Fujita T Kishimoto S Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth Nature 1990 348 6301 555 557 1701033
   PubMed Web of Science ®Google Scholar
• Yeh JR Ju R Brdlik CM Targeted gene disruption of methionine aminopeptidase 2 results in an embryonic gastrulation defect and endothelial cell growth arrest Proc Natl Acad Sci U S A 2006 103 27 10379 10384 16790550
   PubMed Web of Science ®Google Scholar
• White HM Acton AJ Considine RV The angiogenic inhibitor TNP-470 decreases caloric intake and weight gain in high-fat fed mice Obesity (Silver Spring) 2012 20 10 2003 2009 22510957
   PubMed Web of Science ®Google Scholar
• Brakenhielm E Cao Y Angiogenesis in adipose tissue Methods Mol Biol 2008 456 65 81 18516553
   PubMedGoogle Scholar
• Kim YM An JJ Jin YJ Assessment of the anti-obesity effects of the TNP-470 analog, CKD-732 J Mol Endocrinol 2007 38 4 455 465 17446235
   PubMed Web of Science ®Google Scholar
• Hughes TE Kim DD Marjason J Proietto J Whitehead JP Vath JE Ascending dose-controlled trial of beloranib, a novel obesity treatment for safety, tolerability, and weight loss in obese women Obesity (Silver Spring) 2013 21 9 1782 1788 23512440
   PubMed Web of Science ®Google Scholar
• Datta B Majumdar A Datta R Balusu R Treatment of cells with the angiogenic inhibitor fumagillin results in increased stability of eukaryotic initiation factor 2-associated glycoprotein, p67, and reduced phosphorylation of extracellular signal-regulated kinases Biochemistry 2004 43 46 14821 14831 15544353
   PubMed Web of Science ®Google Scholar
• Raghow R Yellaturu C Deng X Park EA Elam MB SREBPs: the crossroads of physiological and pathological lipid homeostasis Trends Endocrinol Metab 2008 19 2 65 73 18291668
   PubMed Web of Science ®Google Scholar
• Kotzka J Knebel B Avci H Phosphorylation of sterol regulatory element-binding protein (SREBP)-1a links growth hormone action to lipid metabolism in hepatocytes Atherosclerosis 2010 213 1 156 165 20863500
   PubMed Web of Science ®Google Scholar
• Hughes TE Kim DD Marjason J Proietto J Whitehead JP Vath JE Ascending dose-controlled trial of beloranib, a novel obesity treatment for safety, tolerability, and weight loss in obese women Obesity (Silver Spring) 2013 21 9 1782 1788 23512440
   PubMed Web of Science ®Google Scholar
• Baratta R Amato S Degano C Adiponectin relationship with lipid metabolism is independent of body fat mass: evidence from both cross-sectional and intervention studies J Clin Endocrinol Metab 2004 89 6 2665 2671 15181039
   PubMed Web of Science ®Google Scholar
• Zhang P Nicholson DE Bujnicki JM Angiogenesis inhibitors specific for methionine aminopeptidase 2 as drugs for malaria and leishmaniasis J Biomed Sci 2002 9 1 34 40 11810023
   PubMed Web of Science ®Google Scholar
• Zafgen [webpage on the Internet] Cambridge Zafgen 2013 Available from: http://zafgen.com/zafgen/our-approach/the-science Accessed October 22, 2013
   Google Scholar
• Lijnen HR Frederix L Van Hoef B Fumagillin reduces adipose tissue formation in murine models of nutritionally induced obesity Obesity (Silver Spring) 2010 18 12 2241 2246 20094042
   PubMed Web of Science ®Google Scholar
• Sin N Meng L Wang MQ Wen JJ Bornmann WG Crews CM The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2 Proc Natl Acad Sci U S A 1997 94 12 6099 6103 9177176
   PubMed Web of Science ®Google Scholar
• Killough JH Magill GB A comparative study of fumagillin and oxytetracycline in amebiasis Am J Trop Med Hyg 1954 3 6 999 1007 13207553
   PubMed Web of Science ®Google Scholar
• Kusaka M Sudo K Fujita T Potent anti-angiogenic action of AGM-1470: comparison to the fumagillin parent Biochem Biophys Res Commun 1991 174 3 1070 1076 1705118
   PubMed Web of Science ®Google Scholar
• Garrabrant T Tuman RW Ludovici D Small molecule inhibitors of methionine aminopeptidase type 2 (MetAP-2) Angiogenesis 2004 7 2 91 96 15516829
   PubMedGoogle Scholar
• Bråkenhielm E Cao R Gao B Angiogenesis inhibitor, TNP-470, prevents diet-induced and genetic obesity in mice Circ Res 2004 94 12 1579 1588 15155527
   PubMed Web of Science ®Google Scholar
• Rupnick MA Panigrahy D Zhang CY Adipose tissue mass can be regulated through the vasculature Proc Natl Acad Sci U S A 2002 99 16 10730 10735 12149466
   PubMed Web of Science ®Google Scholar
• White HM Acton AJ Considine RV The angiogenic inhibitor TNP-470 decreases caloric intake and weight gain in high-fat fed mice Obesity (Silver Spring) 2012 20 10 2003 2009 22510957
   PubMed Web of Science ®Google Scholar
• Chun E Han CK Yoon JH Sim TB Kim YK Lee KY Novel inhibitors targeted to methionine aminopeptidase 2 (MetAP2) strongly inhibit the growth of cancers in xenografted nude model Int J Cancer 2005 114 1 124 130 15523682
   PubMed Web of Science ®Google Scholar
• Kim YM An JJ Jin YJ Assessment of the anti-obesity effects of the TNP-470 analog, CKD-732 J Mol Endocrinol 2007 38 4 455 465 17446235
   PubMed Web of Science ®Google Scholar
• Hughes TE Nichols AJ Vath JE ZGN-201 (ZGN), a methionine aminopeptidase 2 (MetAP2) inhibitor, durably eliminates excess body fat in obese mice through regulation of fat metabolism and food intake Poster presented at: European Association for the Study of Diabetes September 20–24, 2010 Stockholm, Sweden Presentation 244
   Google Scholar
• Hughes TE Vath JE Scott MF ZGN -201, a methionine aminopeptidase 2 inhibitor, normalizes glucose tolerance in overweight dogs Abstract presented at: American Diabetes Association’s 70th Scientific Sessions June 25–29, 2010 Orlando, FL Abstract number 24-LB
   Google Scholar
• Zafgen [website on the Internet] Press releases Cambridge Zafgen 2013 Available from: http://zafgen.com/zafgen/newsroom/press-releases Accessed October 22, 2013
   Google Scholar
• Cao Y Adipose tissue angiogenesis as a therapeutic target for obesity and metabolic diseases Nat Rev Drug Discov 2010 9 2 107 115 20118961
   PubMed Web of Science ®Google Scholar
• Powell AG Apovian CM Aronne LJ New drug targets for the treatment of obesity Clin Pharmacol Ther 2011 90 1 40 51 21654742
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration Orlistat City: Publisher; Year. Available from: http://www.fda.gov/downloads/drugs/developmentapprovalprocess/developmentresources/ucm163348.pdf Accessed October 22, 2013
   Google Scholar
• Drugs Information Online [website on the Internet] Phentermine City Drugs.com 2014 Available from: http://www.drugs.com/monograph/phentermine.html Accessed on October 22, 2013
   Google Scholar
• US Food and Drug Administration [website on the Internet] FDA approves Belviq to treat some overweight or obese adults Silver Spring US Food and Drug Administration 2012 Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm309993.htm Accessed on October 22, 2013
   Google Scholar
• US Food and Drug Administration [website on the Internet] FDA approves weight-management drug Qysmia Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm312468.htm Accessed October 22, 2013
   Google Scholar
• Gadde KM Yonish GM Foust MS Wagner HR Combination therapy of zonisamide and bupropion for weight reduction in obese women: a preliminary, randomized, open-label study J Clin Psychiatry 2007 68 8 1226 1229 17854247
   PubMed Web of Science ®Google Scholar
• Appel L Bergström M Buus Lassen J Långström B Tesofensine, a novel triple monoamine re-uptake inhibitor with anti-obesity effects: Dopamine transporter occupancy as measured by PET Eur Neuropsychopharmacol 2013
   Web of Science ®Google Scholar
• Kopelman P Groot Gde H Rissanen A Weight loss, HbA1c reduction, and tolerability of cetilistat in a randomized, placebo-controlled phase 2 trial in obese diabetics: comparison with orlistat (Xenical) Obesity (Silver Spring) 2010 18 1 108 115 19461584
   PubMed Web of Science ®Google Scholar
• Naltrexone/bupropion: Contrave(R); naltrexone SR/bupropion SR Drugs R D 2010 10 1 25 32 20509712
   PubMedGoogle Scholar
• Hughes TE Kim DD Marjason J Proietto J Whitehead JP Vath JE Ascending dose-controlled trial of beloranib, a novel obesity treatment for safety, tolerability, and weight loss in obese women Obesity (Silver Spring) 2013 21 9 1782 1788 23512440
   PubMed Web of Science ®Google Scholar
• Drugs Information Online [website on the Internet] Shionogi announces positive top-line efficacy results from year-long studies of Velneperit, a novel NPY Y5 receptor antagonist being investigated for the treatment of obesity City Drugs.com 2014 Available from: http://www.drugs.com/clinical_trials/shionogi-announces-positive-top-line-efficacy-results-year-long-studies-velneperit-novel-npy-y5-6742.html Accessed October 22, 2013
   Google Scholar
• Rhythm Pharmaceuticals, Inc Phase 2 study to evaluate safety and efficacy of rm-493 in obese patients Available from: http://clinicaltrials.gov/show/NCT01749137. NLM Identifier: NCT01749137 Accessed October 22, 2013
   Google Scholar
• Bristol-Myers Squibb A study to examine the long term effect of Pramlintide on body weight in obese subjects Available from: http://clinicaltrials.gov/ct2/show/NCT00189514?term=Pramlintide&rank=4. NLM Identifier: NCT00189514 Accessed October 22, 2013
   Google Scholar
• Transitiontherapeutics.com TT-401 Available from http://www.transitiontherapeutics.com/media/news.php Accessed on October 22, 2013
   Google Scholar
• Tan TM Field BC Minnion JS Pharmacokinetics, adverse effects and tolerability of a novel analogue of human pancreatic polypeptide, PP 1420 Br J Clin Pharmacol 2012 73 2 232 239 21834938
   PubMed Web of Science ®Google Scholar
• Dodds CM O’Neill B Beaver J Effect of the dopamine D3 receptor antagonist GSK598809 on brain responses to rewarding food images in overweight and obese binge eaters Appetite 2012 59 1 27 33 22445776
   PubMed Web of Science ®Google Scholar
• ZEAL& [webpage on the Internet]. ZP-2929 Glostrup Zealand Pharma A/s 2012 Available from: http://www.zealandpharma.com/product-pipeline/cardio-metabolic-diseases/drug-candidates-for-diabetes-and-metabolic-diseases/zp2929 Accessed October 22, 2013
   Google Scholar